WO2023080575A1 - 입도분포 유지 안정성이 개선된 알부민 결합 탄산 나노입자 제조방법 - Google Patents
입도분포 유지 안정성이 개선된 알부민 결합 탄산 나노입자 제조방법 Download PDFInfo
- Publication number
- WO2023080575A1 WO2023080575A1 PCT/KR2022/016812 KR2022016812W WO2023080575A1 WO 2023080575 A1 WO2023080575 A1 WO 2023080575A1 KR 2022016812 W KR2022016812 W KR 2022016812W WO 2023080575 A1 WO2023080575 A1 WO 2023080575A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- nanoparticles
- albumin
- particle size
- present
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 131
- 239000002245 particle Substances 0.000 title claims abstract description 70
- 102000009027 Albumins Human genes 0.000 title claims abstract description 56
- 108010088751 Albumins Proteins 0.000 title claims abstract description 56
- 238000009826 distribution Methods 0.000 title claims abstract description 36
- 229940123237 Taxane Drugs 0.000 title claims abstract description 27
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 51
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 61
- 229930012538 Paclitaxel Natural products 0.000 claims description 56
- 229960001592 paclitaxel Drugs 0.000 claims description 56
- 238000001035 drying Methods 0.000 claims description 39
- 238000000265 homogenisation Methods 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 11
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 10
- 239000003125 aqueous solvent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 108010058846 Ovalbumin Proteins 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 229940092253 ovalbumin Drugs 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 25
- 239000000243 solution Substances 0.000 description 101
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 230000000052 comparative effect Effects 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000010790 dilution Methods 0.000 description 36
- 239000012895 dilution Substances 0.000 description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 18
- 238000004108 freeze drying Methods 0.000 description 14
- 238000013341 scale-up Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000001291 vacuum drying Methods 0.000 description 8
- 229940028652 abraxane Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000007972 injectable composition Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010924 continuous production Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- -1 4-methyl-2-propanone Chemical compound 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a method for preparing albumin-bound taxane nanoparticles with improved particle size distribution maintenance stability.
- a poorly soluble drug refers to a drug that is poorly soluble in water because the compound contains a hydrophobic site in its structure, and its practicality is often limited due to its poor solubility. For example, about 41% or more of drugs developed as new drugs are abandoned due to poor solubility, and about 1/3 or more of drugs listed in the US Pharmacopeia are classified as poorly soluble drugs. In order to use these poorly soluble drugs, additional substances to solve the poor solubility must be added, but there are many cases in which use is limited due to the toxicity of the substances added. For example, in general, emulsification using emulsifiers and capture using liposomes are widely used to solubilize poorly soluble substances in water. The situation is.
- Paclitaxel is a drug containing a diterpenoid derivative extracted from the bark of Taxus brevifolia. It is basically composed of a taxane ring and an ester side chain. It has an alkaloid structure. Paclitaxel is known to have anti-cell division activity that promotes the conversion of tubulin complexes into stable microtubules, and is known to be effective against various cancers such as lung cancer and breast cancer. As such, paclitaxel showed excellent potential as an anticancer drug, but its wide use in the field of cancer treatment has been limited due to its low solubility in water.
- paclitaxel was previously used by dissolving it in ethanol, but recently, in order to increase delivery efficiency, paclitaxel is combined with albumin and used as an injection.
- Cremophor EL which is a mixture of polyoxyethylated castor oil and absolute ethanol
- Taxol TM A commercially available formulation in this form is Taxol TM .
- side effects such as cardiotoxicity, neurotoxicity, neurological disorder and hypersensitivity appear when such solvents are clinically administered in excess.
- Abraxane TM is a formulation of paclitaxel combined with human serum albumin in the form of nanoparticles in order to overcome the disadvantages of Taxol such as side effects caused by the solvent, and improved tumor response through human and animal experiments. It has been used as a successful anti-cancer treatment to date.
- Prior Patent Document 1 PCT/US1998/013272 relating to Abraxane
- a mixture of paclitaxel and albumin must be homogenized under high pressure and then quickly dried under reduced pressure. If not performed, the particle size of the nanoparticles containing paclitaxel and albumin significantly increases over time.
- the concentrations of the starting material, the paclitaxel solution and the albumin solution are 7.5% (w / v) and 3% (w / v), respectively, based on Example 5, so scale-up equipment is configured as it is.
- the volume of the equipment such as the mixing tank must be large, and furthermore, since the concentration process must be performed in order to reduce the volume of the final dispersion, a problem in that the production of nanoparticles is significantly reduced occurs.
- an object of the present invention is to provide a method for preparing nanoparticles containing taxanes and albumin with improved particle size distribution maintenance stability.
- Another object of the present invention is to provide nanoparticles containing taxane and albumin prepared by the above preparation method.
- Another object of the present invention is to provide a method for maintaining and stabilizing the particle size distribution of nanoparticles containing taxane and albumin.
- the term "about” as used herein includes numerical limitations, e.g., temperature, time, pressure, amount, concentration, etc., including ranges (+) or (-) 10%, 5%, 4% , 3%, 2%, 1%, or ranges or specific values therebetween.
- nanoparticle means a particle having a particle size dimension of less than 1 ⁇ m.
- the nanoparticles of the present invention are intended for intravenous injection, the nanoparticles preferably have a size of 500 nm or less.
- the nanoparticles are 50-500 nm, 50-400 nm, 50-300 nm, 50-200 nm, 50-190 nm, 50-180 nm, 50-170 nm, 50-160 nm, 50-150 nm , 80-500 nm, 80-400 nm, 80-300 nm, 80-200 nm, 80-190 nm, 80-180 nm, 80-170 nm, 80-160 nm, 80-150 nm, 100-500 nm , 100-400 nm, 100-300 nm, 100-200 nm, 100-190 nm, 100-180 nm, 100-170 nm, 100-160 nm, 100-150 nm, 110-500 nm, 110-400 nm , 110-300 nm, 110-200 nm, 110-190 nm, 110-180 nm, 110-170 nm, 110-160 nm,
- the size of the population of particles can be represented by means and/or percentiles.
- D 10 means that 10% of the particles are smaller than that size
- D 50 means that 50% of the particles are smaller than that size
- D 90 means that 90% of the particles are smaller than that size.
- the average particle size can be expressed as D 50 .
- the concentration of taxanes in the first solution is 55 to 75% (w/v), 60 to 75% (w/v), 65 to 75% (w/v), 70 to 75% (w/v). 75% (w/v), 55 to 70% (w/v), 55 to 65% (w/v), 55 to 60% (w/v), 60 to 70% (w/v), 64 to 60% 68% (w/v), or 65 to 67% (w/v).
- the solvent of the first solution is ethanol, methanol, isopropyl alcohol, butanol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile, It is selected from the group consisting of dichloromethane, ethyl acetate, hexane, diethyl ether, benzene, chloroform, acetone, and combinations thereof, but is not limited thereto.
- DMSO dimethyl sulfoxide
- DMF dimethylformamide
- THF tetrahydrofuran
- acetonitrile It is selected from the group consisting of dichloromethane, ethyl acetate, hexane, diethyl ether, benzene, chloroform, acetone, and combinations thereof, but is not limited thereto.
- the solvent of the first solution is a mixed solvent of ethanol and chloroform.
- the ethanol:chloroform volume ratio is 1:5 to 1:20, 1:6 to 1:20, 1:7 to 1:20, 1:8 to 1:20, 1:9 to 1:20, 1:10 to 1:20, 1:12 to 1:20, 1:14 to 1:20, 1:15 to 1:20, 1:5 to 1:18, 1:6 to 1:18, 1:7 to 1 :18, 1:8 to 1:18, 1:9 to 1:18, 1:10 to 1:18, 1:12 to 1:18, 1:14 to 1:18, 1:15 to 1:18 , 1:5 to 1:16, 1:6 to 1:16, 1:7 to 1:16, 1:8 to 1:16, 1:9 to 1:16, 1:10 to 1:16, 1 :12 to 1:16, 1:16, 1:14 to 1:16, 1:15 to 1:16, 1:5 to 1:15, 1:6 to 1:15, 1:7 to 1:15, 1:8 to 1:15, 1:9 to 1:15, 1:10 to 1:15, 1:12 to 1:15,
- the injectable formulation when the taxane concentration of the first solution is less than the lower limit of the range of 55 to 75% (w/v) defined in the present invention, even if the water dilution step is performed, the injectable formulation is effective before drying under reduced pressure. There is a problem that the particle size rises rapidly to 200 nm or more to the extent that it cannot be used as a component.
- the taxane concentration of the first solution exceeds the upper limit of the range of 55 to 75% (w/v) defined in the present invention
- paclitaxel is precipitated during the nanoparticle manufacturing process, making normal operation of the high-pressure homogenizer impossible, and nanoparticles
- the particle size also increases, causing a problem that nanoparticles of uniform particle size cannot be produced at a concentration exceeding 75% (w / v).
- the taxane may be paclitaxel, docetaxel, or a combination thereof, but is not limited thereto.
- the concentration of albumin in the second solution is 15 to 25% (w / v), 18 to 25% (w / v), 22 to 25% (w / v), 15 to 25% (w / v) It may be 22% (w/v), 15 to 18% (w/v), 18 to 22% (w/v), or 19 to 21% (w/v).
- the solvent of the second solution is water, distilled water, sterile water, phosphate buffered saline (PBS), methanol, purified water, ethanol, 1-propanol, 2-propanol, 1-pentanol,
- An aqueous solvent selected from the group consisting of 2-butoxyethanol, ethylene glycol, acetone, 2-butanone, 4-methyl-2-propanone, chloroform, and combinations thereof, but is not limited thereto.
- the weight ratio of paclitaxel:albumin in the final nanoparticles is 1:9, the same as that of Abraxane TM .
- the volume of the dispersion must be excessively increased, and as a result, an additional concentration process is required outside the usual filling volume range, resulting in a problem that is practically difficult for industrial use.
- albumin concentration of the second solution exceeds the upper limit of the range of 15 to 25% (w / v) defined in the present invention, even if the water dilution step is performed, the average is not usable as an active ingredient of the injectable formulation before drying under reduced pressure. A problem arises in which the particle size rapidly rises above 200 nm.
- the albumin may be human serum albumin (HSA), bovine serum albumin (BSA), ovalbumin (OVA), or a combination thereof.
- HSA human serum albumin
- BSA bovine serum albumin
- OVA ovalbumin
- the mixing volume ratio of the first solution and the second solution in step (c) is 1:20 to 1:45, but is not limited thereto.
- the mixing volume ratio of the first solution and the second solution is 1:20 to 1:43, 1:20 to 1:41, 1:20 to 1:39, 1:20 to 1:37, 1:20 to 1:35, 1:20 to 1:33, 1:20 to 1:31, 1:20 to 1:29, 1:20 to 1:27, 1:20 to 1:25, 1:20 to 1 :23, 1:20 to 1:21, 1:22 to 1:45, 1:24 to 1:45, 1:26 to 1:45, 1:28 to 1:45, 1:30 to 1:45 , 1:32 to 1:45, 1:34 to 1:45, 1:36 to 1:45, 1:38 to 1:45, 1:40 to 1:45, 1:42 to 1:45, 1 :44 to 1:45, 1:22 to 1:40, 1:25
- the weight ratio of paclitaxel:albumin in the final nanoparticles is prepared to be about 1:9, the same as that of Abraxane TM . .
- the weight ratio of paclitaxel:albumin is not necessarily limited to about 1:9, and may be in the range of 1:7 to 11, 1:8 to 10, or 1:8.5 to 9.5.
- the preparation of the suspension in step (c) is performed by high pressure homogenization.
- the high pressure homogenization is performed at a temperature condition of 10 to 40 ° C, 15 to 40 ° C, 20 to 40 ° C, 30 to 40 ° C, or 35 to 40 ° C, but is not limited thereto .
- the high pressure homogenization is 10,000 to 30,000 psi, 12,000 to 30,000 psi, 15,000 to 30,000 psi, 16,000 to 30,000 psi, 17,000 to 30,000 psi, 18,000 to 30,000 psi, 10,000 to 25,000 psi, 12,000 to 25,000 psi, 15,000 to 25,000 psi, 16,000 to 25,000 psi, 17,000 to 25,000 psi, 18,000 to 25,000 psi, 10,000 to 20,000 psi, 12,000 to 20,000 psi, 15, 000 to 20,000 psi, 16,000 to 20,000 psi, 17,000 to 20,000 psi, or 18,000 to 20,000 psi, but is not limited thereto.
- the high-pressure homogenization is performed one or more times, more specifically 1 to 5 times, 1 to 4 times, or 1 to 3 times, but is not limited thereto.
- the dilution in step (d) is 3 to 12 times, 5 to 12 times, 7 to 12 times, 10 to 12 times, 3 to 10 times, or 3 to 7 times based on the volume of the suspension. , It may be diluted 3 to 5 times, 5 to 10 times, or 5 to 7 times, but is not limited thereto.
- the particle size is 200 nm or more to the extent that it cannot be used as an active ingredient of an injectable formulation before drying under reduced pressure even after performing the water dilution step.
- the increase in particle size may be due to agglomeration between nanoparticles. Aggregation of nanoparticles can block blood vessels in the case of nanoparticles for intravenous injection. Therefore, aggregation of nanoparticles and stability of nanoparticles may affect the efficacy and safety of a pharmaceutical composition containing nanoparticles.
- the amount of the aqueous solvent used exceeds the upper limit of the range of 3 to 12 times defined in the present invention, the free fraction of paclitaxel, that is, the unencapsulated rate increases (when diluted with 5.3 times water, the unencapsulated rate 0.72% ⁇ 13 6.24% of non-encapsulation rate when diluting with double volume water), and water more than necessary for stabilizing the particle size of nanoparticles causes problems that are not efficient and economical in terms of scale-up process.
- the average particle size of the nanoparticles in the diluted solution in step (d) is 100 to 200 nm, or 110 to 190 nm, but is not limited thereto.
- the preparation method may further include (e) drying the diluted solution to obtain nanoparticles.
- the drying may be reduced pressure drying, freeze drying, or heat drying, but is not limited thereto.
- the drying according to one embodiment of the present invention is reduced pressure drying, it can be carried out by adopting a conventional reduced pressure drying method such as using a rotary evaporator, and is not limited to specific reduced pressure drying conditions.
- the reduced pressure drying is 10 to 70 °C, 20 to 70 °C, 30 to 70 °C, 40 to 70 °C, 10 to 60 °C, 10 to 50 °C, 10 to 40 °C, 20 to 60 °C, 30 to 50 °C, 35 to 45 °C, 38 to 42 °C, or 39 to 41 °C, but may be made under temperature conditions in the range, but is not limited thereto.
- the vacuum drying is 10 to 110 hPa, 20 to 110 hPa, 30 to 110 hPa, 40 to 110 hPa, 50 to 110 hPa, 10 to 100 hPa, 10 to 90 hPa, 10 to It may be made under pressure conditions ranging from 80 hPa, 10 to 70 hPa, 20 to 100 hPa, 30 to 90 hPa, 40 to 80 hPa, 50 to 70 hPa, or 55 to 65 hPa, but is not limited thereto.
- the nanoparticles present in the diluted solution may maintain an average particle size of 100 to 200 nm, preferably 110 to 190 nm, from before drying to completion of drying.
- the average size of nanoparticles in the dilution solution with water before drying under reduced pressure compared to the conventional process of quickly drying under reduced pressure after high-pressure homogenization without performing a dilution step with water is maintained uniformly over time, showing remarkable effects in structural stability and particle size distribution, and these effects of the present invention are supported by Examples, Comparative Examples, and Experimental Examples to be described later.
- nanoparticles containing taxane and albumin prepared by the method according to one aspect of the present invention are provided.
- the nanoparticles containing the taxane and albumin prepared by the manufacturing method according to one aspect of the present invention are reconstituted in an aqueous solvent (including in vivo and in vitro ). Upon reconstitution, it has substantially the same therapeutic activity and particle properties as the properties of the nanoparticles before drying (eg, the nanoparticles in the diluted solution in step (d)).
- the average particle size and particle size distribution are substantially the same as those of the nanoparticles before drying.
- the meaning of substantially the same means that the parameters for the nanoparticles immediately after freeze-drying compared to the parameters for the nanoparticles before freeze-drying are in the range of ⁇ 10%, more specifically in the range of ⁇ 7%, in the range of ⁇ 5%, in the range of ⁇ 4%, or within the ⁇ 3.5% range.
- the dried nanoparticles are stored at room temperature for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.
- the nanoparticles are stable for the above period, and even after being stored at room temperature for the above period and reconstituted in an aqueous solvent, the nanoparticles show therapeutic activity and particle characteristics before drying.
- the drying is lyophilization.
- the freeze-drying refers to a process in which nanoparticles, which are materials to be dried, are frozen, and then the frozen solvent is removed by sublimation in a vacuum environment.
- an excipient or cryoprotectant is optionally included to enhance the storage stability of the lyophilized product.
- excipients or cryoprotectants include polymers such as dextran and polyethylene glycol; sugars such as sucrose, glucose, trehalose, and lactose; surfactants such as polysorbates; and amino acids such as glycine, arginine, and serine.
- the nanoparticle may further include one or more additional therapeutic agents in addition to the taxane of the present invention.
- the nanoparticles can be pharmaceutically formulated for administration to patients.
- a variety of formulations and drug delivery systems are available in the art. See, for example, Gennaro, A.R., ed. (1995) Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co.
- nanoparticles of the present invention can be administered as a pharmaceutical composition by one of the following routes: orally; Parenteral, such as transdermal, intranasal, intramuscular, intravenous, subcutaneous, intradermal, intratumoral, etc.
- the nanoparticles of the present invention may include the following solid, liquid, semi-solid, or gaseous excipients.
- the solid pharmaceutical excipients are starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, and the like.
- the liquid and semi-solid excipients may be glycerol, propylene glycol, water, ethanol and various oils including oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil. , sesame oil, and the like.
- Preferred liquid carriers, particularly liquid carriers for injectable solutions include water, saline, aqueous dextrose, and glycols.
- Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- the nanoparticles are formulated for intravenous injection. In another specific embodiment of the invention, the nanoparticles are formulated for direct injection or perfusion into a tumor.
- the present invention provides a method for maintaining and stabilizing the particle size distribution of nanoparticles, comprising the steps of:
- the method for maintaining and stabilizing the particle size distribution of nanoparticles according to one aspect of the present invention includes the same steps (a) to (d) as the method for producing nanoparticles according to one aspect of the present invention described above, Common content is omitted to avoid redundant description in this specification.
- the method for producing nanoparticles containing taxane and albumin of the present invention maintains a uniform average size of nanoparticles over time, resulting in excellent structural stability and particle size distribution. Therefore, it can be usefully used as an improved method for preparing nanoparticles containing taxanes and albumin.
- % used to indicate the concentration of a particular substance is (weight/weight) % for solids/solids, (weight/volume) % for solids/liquids, and liquid/liquid is (volume/volume) %.
- Nanoparticles containing paclitaxel and albumin were prepared according to the method of Example 4 of Prior Patent Document 1 (PCT/US1998/013272). Specifically, 30 mg of paclitaxel was dissolved in chloroform/ethanol solvent (11:1 v/v) in which 0.55 ml of chloroform and 0.05 ml of ethanol were mixed to obtain a 5% (w/v) concentration of paclitaxel solution (first solution). prepared. In addition, 29.4 ml of a 1% (w/v) human serum albumin (HSA) solution (second solution) previously saturated with 1% chloroform was prepared.
- HSA human serum albumin
- the first solution and the second solution prepared above were mixed, and the mixture was mixed in an IKA homogenizer (T-25) at 5,600 rpm for 5 minutes to form a crude emulsion, then the mixture was transferred to a Micronox (MN400BF), 22 ° C and 2 cycles, high pressure homogenization under the condition of 18,000 psi.
- the mixed solution after high pressure homogenization was transferred to a rotary evaporator and dried under reduced pressure at 40° C. and 60 hPa to quickly remove chloroform for 15 to 30 minutes to prepare nanoparticles containing paclitaxel and albumin.
- Nanoparticles containing paclitaxel and albumin were prepared according to the method of Example 5 of Prior Patent Document 1 (PCT/US1998/013272). Specifically, 225 mg of paclitaxel was dissolved in a chloroform/ethanol solution (9:1 v/v) in which 2.7 ml of chloroform and 0.3 ml of ethanol were mixed to obtain a 7.5% (w/v) paclitaxel solution (first solution). prepared. In addition, 97 ml of a 3% (w/v) human serum albumin (HSA) solution (second solution) was prepared.
- HSA human serum albumin
- the first solution and the second solution prepared above were mixed, and the mixture was mixed in an IKA homogenizer (T-25) at 5,600 rpm for 5 minutes to form a crude emulsion, then the mixture was transferred to a Micronox (MN400BF), 22 ° C and 2 cycles, high pressure homogenization under the condition of 18,000 psi.
- the mixed solution after high pressure homogenization was transferred to a rotary evaporator and dried under reduced pressure at 40° C. and 60 hPa to quickly remove chloroform for 15 to 30 minutes to prepare nanoparticles containing paclitaxel and albumin.
- the present inventors prepared nanoparticles containing paclitaxel and albumin as follows.
- the experimental protocol below corresponds to Example 3 in Table 1 below.
- paclitaxel solution 1 g was dissolved in 1.5 ml chloroform/ethanol solvent (14:1 v/v) in which chloroform and ethanol were mixed at a volume ratio of 14:1 to obtain a 66.7% (w/v) paclitaxel solution (first solution).
- first solution 1 g was dissolved in 1.5 ml chloroform/ethanol solvent (14:1 v/v) in which chloroform and ethanol were mixed at a volume ratio of 14:1 to obtain a 66.7% (w/v) paclitaxel solution (first solution).
- first solution 66.7% (w/v) paclitaxel solution
- second solution Green Cross Albumin 20%, Greencross Human Serum Albumin Inj. 20%
- the mixture was transferred to Micronox (MN400BF) and homogenized under high pressure for 2 cycles at 22°C and 18,000 psi.
- the mixed solution after high-pressure homogenization was diluted with 5.3-fold volume of water.
- the diluted mixed solution was dried under reduced pressure at 40 ° C. and 60 hPa using a rotary evaporator to prepare nanoparticles containing paclitaxel and albumin.
- nanoparticles were prepared by varying the concentration of the first solution, the concentration of the second solution, or the water used for dilution, and the specific variable conditions for each example are shown in Table 1 below. shown in Table 1 below.
- the mixed volume ratio of the first solution and the second solution was determined according to the concentration of the first solution and the second solution, which is the weight ratio of paclitaxel: albumin in the nanoparticles finally prepared Abraxane ® This is to be prepared in the same way as 1:9.
- Example First solution concentration, % (w/v) Second solution concentration, % (w/v) water use Doubling 1st, 2nd solution mixing volume ratio One 55.0 20 5.3 1:24.8 2 60.0 1:27.0 3 66.7 1:30.0 4 70.0 1:31.5 5 75.0 1:33.8 6 66.7 15 5.3 1:40.0 7 18 1:33.4 8 22 1:27.3 9 25 1:24.0 10 66.7 20 3.0 1:30.0 11 5.0 12 7.0 13 10.0 14 12.0 Comparative Example 1 5 One - 1:49.0 Comparative Example 2 7.5 3 - 1:32.3
- Examples 1 to 14 described in Table 1 and the manufacturing methods described in Examples 4 and 5 of Prior Patent Document 1 are: i) the first The concentrations of the first solution and the second solution are different, and ii) there is a difference in whether or not a step of diluting with water is additionally included before the step of drying the mixed solution after high pressure homogenization under reduced pressure.
- nanoparticles containing paclitaxel and albumin were prepared in the same manner as in Examples 1 to 14 except for the water dilution step before drying under reduced pressure. manufactured. Variable conditions for each comparative example are shown in Table 2 below.
- first solution concentration % (w / v)
- second solution concentration % (w / v)
- the present inventors set i) the first solution concentration (% (w / v)), ii) the second solution concentration (% (w / v)), and iii) dilution set in Examples 1 to 14 of the present invention
- Experiments of Comparative Examples 13 to 24 were performed in order to determine how the amount of water used in was affected on the quality of nanoparticles containing paclitaxel and albumin.
- the mixing volume ratio of the first and second solutions in the table below was determined according to the concentrations of the first solution and the second solution, which is the ratio of paclitaxel:albumin in the nanoparticles finally prepared. This is to ensure that the weight ratio is 1:9, the same as that of Abraxane®.
- the stability of the particle size of the nanoparticle product during the manufacturing process is secured, making it economical, efficient and scaleable. It can be actively utilized as a technology suitable for business.
- the particle size distribution of nanoparticles in the mixture (water dilution in the case of the examples) before drying under reduced pressure, prepared in the conventional method of manufacturing Comparative Examples 1 and 2 and the manufacturing method of Examples 1 to 14 of the present invention, is It was compared and evaluated whether it remained stable over time.
- Example 1 146.5 156.8 157.8 158.9 157.5 159.3 160.2
- Example 2 151.1 151.2 151.8 152.3 151.7 152.8 151.8
- Example 3 155.3 156.4 154.8 155.2 155.3 154.8 154.6
- Example 4 156.7 156.2 155.8 157.8 156.8 157.2 158.4
- Example 5 160.6 159.8 160.1 160.8 161.2 160.8 159.8
- Example 6 153.5 153.2 153.9 154.2 154.8 153.2 153.8
- Example 7 154.1 153.8 154.5 156.5 155.8 154.2 155.7
- Example 8 153.3 153.1 152.8 154.7 154.2 154.7 154.3
- Example 9 153.3 161.2 163.5 164.2 163.2 164.2 163.2
- Example 10 150.3 175.4 178.6 179.2 178.6 179.5 178.8
- Example 11 155.2 154.8 154.9 155.4 155.8 154.1 153.7
- Example 12 153.6 154.8 153.4 155.2 153.8 154.2 152.6
- Example 13 149.8
- the manufacturing method of the present invention (Examples 1 to 14), which includes the step of diluting with water after high pressure homogenization and before vacuum drying, quickly dried under reduced pressure after high pressure homogenization without performing the dilution step with water
- the manufacturing method of the present invention (Examples 1 to 14), which includes the step of diluting with water after high pressure homogenization and before vacuum drying, quickly dried under reduced pressure after high pressure homogenization without performing the dilution step with water
- Comparative Examples 1 and 2 it can be seen that the size of the nanoparticles is maintained for a long time over time, and thus the structural stability and particle size distribution of the nanoparticles are relatively excellent.
- the nanoparticles of Comparative Examples 1 and 2 corresponding to Examples 4 and 5 of PCT/US1998/013272 had a Z-average (nm) of 430.1 nm to such an extent that they could not be used as an active ingredient of an injectable formulation in 20 minutes after high-pressure homogenization. , it was confirmed that it grew larger than 458.6 nm.
- the nanoparticles of Examples 1 to 14 of the present invention maintain a Z-average (nm) of ⁇ 200 nm even after 120 minutes, and thus the particle size distribution is very excellent.
- the concentrations of the starting material, the paclitaxel solution and the albumin solution are 7.5% (w/v) and 3% (w/v), respectively, based on Example 5, so scale-up facilities remain as they are.
- the volume of equipment such as a mixing tank must be large, and furthermore, since a concentration process must be performed in order to reduce the volume of the final dispersion, a problem in that the production of nanoparticles is significantly reduced occurs.
- the nanoparticle manufacturing method provided in one aspect of the present invention solves the limitation of the process disclosed in PCT/US1998/013272, that is, the problem of rapidly increasing the size of nanoparticles after high-pressure homogenization before vacuum drying.
- an environment suitable for scale-up can be provided in terms of economic feasibility and efficiency.
- Example Z-average (nm) comparative example Z-average (nm) 0 minutes 60 minutes 120 minutes 0 minutes 60 minutes 120 minutes
- One 146.5 158.9 160.2 3 142.2 601.6 687.3 2 151.1 152.3 151.8 4 152.6 586.9 651.2 3 155.3 155.2 154.6 5 154.8 526.2 631.9 4 156.7 157.8 158.4 6 154.2 523.1 625.1 5 160.6 160.8 159.8 7 157.9 503.8 594.2 6 153.5 154.2 153.8 8 152.1 581.8 648.3 7 154.1 156.5 155.7 9 155.8 572.9 637.2 8 153.3 154.7 154.3 10 154.2 598.8 647.3 9 153.3 164.2 163.2 11 155.8 618.9 662.1 10 150.3 179.2 178.8 12 154.8 526.4 631.9 11 155.2 155.4 153.7 12 153.6 155.2 152.6 13 149.8 151.4 152.8 14 151.3 150.2 153.7
- the nanoparticles in the diluted solutions of Examples 1 to 14 of the present invention in which the water dilution step was performed before the drying under reduced pressure after high pressure homogenization, maintained a uniform particle size distribution over time.
- the size of the nanoparticles in the mixed solutions of Comparative Examples 3 to 12, which do not include a water dilution step, rapidly increases over time to the extent that they cannot be used as an active ingredient in an injectable formulation.
- the present inventors determined the particle size distribution of the nanoparticles of the present invention by i) the concentration of the first solution (% (w / v)), ii) the concentration of the second solution (% (w / v)), and iii) the water used for dilution
- nanoparticles were prepared according to Comparative Examples 13 to 24 described above, and the particle size distribution was measured in the same manner as in Experimental Example 1.
- comparative example First solution concentration, % (w/v) Second solution concentration, % (w/v) water use Doubling 1st, 2nd solution mixing volume ratio 21 66.7 20 1.0 1:30.0 22 2.0 23 13.0 24 14.0
- the unencapsulated rate of paclitaxel was confirmed by the following method:
- Example 3 Samples prepared in Example 3 (5.3-fold water dilution) or Comparative Example 23 (13-fold water dilution) were ultrafiltered, and the lower layer was analyzed by HPLC.
- Example 3 when diluted with 5.3-fold amount of water as in Example 3, the unencapsulated rate of paclitaxel was 0.72%, and when diluted with 13-fold amount of water as in Comparative Example 23, the unencapsulated rate of paclitaxel was 6.24%.
- the difference in the manufacturing method between Example 3 and Comparative Example 23 is only in the water dilution factor, and it can be seen that the water dilution factor is an important component in introducing a scale-up process for producing nanoparticles of good quality.
- the nanoparticle manufacturing method according to Examples 1 to 14 of the present invention is typically organically linked to the concentration of the first and second solutions and the step of diluting with water before drying under reduced pressure. , it can be seen that a remarkable effect of maintaining a constant particle size distribution of the nanoparticles in the high-pressure homogenized dilution solution is achieved, and as a result, nanoparticles containing paclitaxel and albumin can be produced with a high yield.
- the dispersion from which the organic solvent was removed through drying under reduced pressure was filtered through a 0.22 ⁇ m pore size filter (Sartorius).
- the filtered liquid was filled in a glass vial for lyophilization and freeze-dried for 72 hours. After lyophilization, 20 ml of tertiary distilled water or 0.9% saline was added to a vial containing the lyophilized powder obtained and redispersed.
- the particle size distribution measurement results are shown in Table 12 below.
- Example Z-average (nm) before freeze drying Re-dissolution after freeze-drying One 146.5 151.6 2 151.1 150.9 3 155.3 154.2 4 156.7 155.4 5 160.6 159.3 6 153.5 153.6 7 154.1 154.8 8 153.3 153.9 9 153.3 154.8 10 150.3 151.4 11 155.2 154.7 12 153.6 153.0 13 149.8 150.4 14 151.3 151.6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
실시예 | 제1 용액 농도, % (w/v) | 제2 용액 농도, % (w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
1 | 55.0 | 20 | 5.3 | 1 : 24.8 |
2 | 60.0 | 1 : 27.0 | ||
3 | 66.7 | 1 : 30.0 | ||
4 | 70.0 | 1 : 31.5 | ||
5 | 75.0 | 1 : 33.8 | ||
6 | 66.7 | 15 | 5.3 | 1 : 40.0 |
7 | 18 | 1 : 33.4 | ||
8 | 22 | 1 : 27.3 | ||
9 | 25 | 1 : 24.0 | ||
10 | 66.7 | 20 | 3.0 | 1 : 30.0 |
11 | 5.0 | |||
12 | 7.0 | |||
13 | 10.0 | |||
14 | 12.0 | |||
비교예 1 | 5 | 1 | - | 1 : 49.0 |
비교예 2 | 7.5 | 3 | - | 1 : 32.3 |
비교예 | 제1 용액 농도, %(w/v) | 제2 용액 농도, %(w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
3 | 55.0 | 20 | X (실시예와 비교하여 물 희석 단계만 수행하지 않음) |
1 : 24.8 |
4 | 60.0 | 1 : 27.0 | ||
5 | 66.7 | 1 : 30.0 | ||
6 | 70.0 | 1 : 31.5 | ||
7 | 75.0 | 1 : 33.8 | ||
8 | 66.7 | 15 | 1 : 40.0 | |
9 | 18 | 1 : 33.4 | ||
10 | 22 | 1 : 27.3 | ||
11 | 25 | 1 : 24.0 | ||
12 | 66.7 | 20 | 1 : 30.0 |
비교예 | 제1 용액 농도, %(w/v) | 제2 용액 농도, %(w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
13 | 45.0 | 20 | 5.3 | 1 : 20.3 |
14 | 50.0 | 1: 22.5 | ||
15 | 80.0 | 1 : 36.0 | ||
16 | 85.0 | 1 : 38.3 | ||
17 | 66.7 | 5 | 5.3 | 1 : 120.0 |
18 | 10 | 1 : 60.0 | ||
19 | 30 | 1: 20.0 | ||
20 | 35 | 1 : 17.1 | ||
21 | 66.7 | 20 | 1.0 | 1 : 30.0 |
22 | 2.0 | |||
23 | 13.0 | |||
24 | 14.0 |
구분 | Z-average (nm) | ||||||
0분 | 20분 | 40분 | 60분 | 80분 | 100분 | 120분 | |
실시예 1 | 146.5 | 156.8 | 157.8 | 158.9 | 157.5 | 159.3 | 160.2 |
실시예 2 | 151.1 | 151.2 | 151.8 | 152.3 | 151.7 | 152.8 | 151.8 |
실시예 3 | 155.3 | 156.4 | 154.8 | 155.2 | 155.3 | 154.8 | 154.6 |
실시예 4 | 156.7 | 156.2 | 155.8 | 157.8 | 156.8 | 157.2 | 158.4 |
실시예 5 | 160.6 | 159.8 | 160.1 | 160.8 | 161.2 | 160.8 | 159.8 |
실시예 6 | 153.5 | 153.2 | 153.9 | 154.2 | 154.8 | 153.2 | 153.8 |
실시예 7 | 154.1 | 153.8 | 154.5 | 156.5 | 155.8 | 154.2 | 155.7 |
실시예 8 | 153.3 | 153.1 | 152.8 | 154.7 | 154.2 | 154.7 | 154.3 |
실시예 9 | 153.3 | 161.2 | 163.5 | 164.2 | 163.2 | 164.2 | 163.2 |
실시예 10 | 150.3 | 175.4 | 178.6 | 179.2 | 178.6 | 179.5 | 178.8 |
실시예 11 | 155.2 | 154.8 | 154.9 | 155.4 | 155.8 | 154.1 | 153.7 |
실시예 12 | 153.6 | 154.8 | 153.4 | 155.2 | 153.8 | 154.2 | 152.6 |
실시예 13 | 149.8 | 150.2 | 150.8 | 151.4 | 150.8 | 151.8 | 152.8 |
실시예 14 | 151.3 | 151.8 | 150.9 | 150.2 | 150.6 | 152.8 | 153.7 |
비교예 1 | 151.3 | 430.1 | 472.7 | 562.8 | 696.1 | 798.5 | 805.3 |
비교예 2 | 158.2 | 458.6 | 508.4 | 578.3 | 689.4 | 781.6 | 813.6 |
실시예 | Z-average (nm) | 비교예 | Z-average (nm) | ||||
0분 | 60분 | 120분 | 0분 | 60분 | 120분 | ||
1 | 146.5 | 158.9 | 160.2 | 3 | 142.2 | 601.6 | 687.3 |
2 | 151.1 | 152.3 | 151.8 | 4 | 152.6 | 586.9 | 651.2 |
3 | 155.3 | 155.2 | 154.6 | 5 | 154.8 | 526.2 | 631.9 |
4 | 156.7 | 157.8 | 158.4 | 6 | 154.2 | 523.1 | 625.1 |
5 | 160.6 | 160.8 | 159.8 | 7 | 157.9 | 503.8 | 594.2 |
6 | 153.5 | 154.2 | 153.8 | 8 | 152.1 | 581.8 | 648.3 |
7 | 154.1 | 156.5 | 155.7 | 9 | 155.8 | 572.9 | 637.2 |
8 | 153.3 | 154.7 | 154.3 | 10 | 154.2 | 598.8 | 647.3 |
9 | 153.3 | 164.2 | 163.2 | 11 | 155.8 | 618.9 | 662.1 |
10 | 150.3 | 179.2 | 178.8 | 12 | 154.8 | 526.4 | 631.9 |
11 | 155.2 | 155.4 | 153.7 | ||||
12 | 153.6 | 155.2 | 152.6 | ||||
13 | 149.8 | 151.4 | 152.8 | ||||
14 | 151.3 | 150.2 | 153.7 |
비교예 | 제1 용액 농도, %(w/v) | 제2 용액 농도, %(w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
13 | 45.0 | 20 | 5.3 | 1 : 20.3 |
14 | 50.0 | 1 : 22.5 | ||
15 | 80.0 | 1 : 36.0 | ||
16 | 85.0 | 1 : 38.3 |
비교예 | Z-average (nm) | ||||||
0분 | 20분 | 40분 | 60분 | 80분 | 100분 | 120분 | |
13 | 149.9 | 189.5 | 205.6 | 227.6 | 231.5 | 236.6 | 231.5 |
14 | 148.4 | 180.9 | 196.8 | 218.6 | 218.1 | 220.8 | 225.9 |
15 | - | - | - | - | - | - | - |
16 | - | - | - | - | - | - | - |
비교예 | 제1 용액 농도, %(w/v) | 제2 용액 농도, %(w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
17 | 66.7 | 5 | 5.3 | 1 : 120.0 |
18 | 10 | 1 : 60.0 | ||
19 | 30 | 1: 20.0 | ||
20 | 35 | 1 : 17.1 |
비교예 | Z-average (nm) | ||||||
0분 | 20분 | 40분 | 60분 | 80분 | 100분 | 120분 | |
19 | 166.4 | 204.2 | 216.8 | 226.5 | 221.5 | 228.8 | 226.7 |
20 | 167.8 | 216.8 | 226.1 | 239.1 | 240.5 | 241.6 | 245.8 |
비교예 | 제1 용액 농도, %(w/v) | 제2 용액 농도, %(w/v) | 물 사용 배량 |
제1, 2 용액 혼합 부피 비 |
21 | 66.7 | 20 | 1.0 | 1 : 30.0 |
22 | 2.0 | |||
23 | 13.0 | |||
24 | 14.0 |
비교예 | Z-average (nm) | ||||||
0분 | 20분 | 40분 | 60분 | 80분 | 100분 | 120분 | |
21 | 153.8 | 242.5 | 268.8 | 278.5 | 271.5 | 289.5 | 281.5 |
22 | 154.2 | 202.7 | 223.8 | 235.8 | 234.6 | 239.5 | 248.1 |
실시예 | Z-average (nm) | |
동결건조 전 | 동결건조 후 재용해시 | |
1 | 146.5 | 151.6 |
2 | 151.1 | 150.9 |
3 | 155.3 | 154.2 |
4 | 156.7 | 155.4 |
5 | 160.6 | 159.3 |
6 | 153.5 | 153.6 |
7 | 154.1 | 154.8 |
8 | 153.3 | 153.9 |
9 | 153.3 | 154.8 |
10 | 150.3 | 151.4 |
11 | 155.2 | 154.7 |
12 | 153.6 | 153.0 |
13 | 149.8 | 150.4 |
14 | 151.3 | 151.6 |
Claims (12)
- 다음 단계를 포함하는 탁산 및 알부민을 포함하는 나노입자 제조방법:(a) 탁산이 55 내지 75 %(w/v)로 용해된 제1 용액을 준비하는 단계;(b) 알부민이 15 내지 25 %(w/v)로 용해된 제2 용액을 준비하는 단계;(c) 제1 용액과 제2 용액을 혼합하여 현탁액을 제조하는 단계; 및(d) 상기 현탁액 부피 기준, 3 내지 12배량의 수성용매로 희석하는 단계.
- 제1항에 있어서, (e) 상기 희석된 용액을 건조하여 나노입자를 수득하는 단계를 추가적으로 포함하는, 제조방법.
- 제2항에 있어서, 상기 희석된 용액 내 존재하는 나노입자는, 건조를 수행하기 이전부터 건조를 완료하기까지 평균 입도가 100 내지 200 nm를 유지하는, 제조방법.
- 제2항에 있어서, 상기 희석된 용액 내 존재하는 나노입자는, 건조를 수행하기 이전부터 건조를 완료하기까지 평균 입도가 110 내지 190 nm를 유지하는, 제조방법.
- 제1항에 있어서, 상기 탁산은 파클리탁셀, 도세탁셀, 또는 이들의 조합인, 제조방법.
- 제1항에 있어서, 상기 알부민은 인간 혈청알부민(human serum albumin, HSA), 소 혈청알부민(bovine serum albumin, BSA), 난 알부민(ovalbumin, OVA), 또는 이들의 조합인, 제조방법.
- 제1항에 있어서, 상기 단계 (c)에서 제1 용액과 제2 용액의 혼합 부피비는 1:20 내지 1:45인, 제조방법.
- 제1항에 있어서, 상기 단계 (c)에서 현탁액의 제조는 고압 균질화(homogenization)에 의해 이루어지는 것인, 제조방법.
- 제8항에 있어서, 상기 고압 균질화는 10 내지 40℃의 온도 조건에서 수행되는 것인, 제조방법.
- 제8항에 있어서, 상기 고압 균질화는 10,000 내지 30,000 psi의 압력 조건에서 수행되는 것인, 제조방법.
- 제1항 내지 제10항 중 어느 한 항의 방법에 의하여 제조되는, 탁산 및 알부민을 포함하는 나노입자.
- 다음 단계를 포함하는 탁산 및 알부민을 포함하는 나노입자의 입도분포 유지 안정화 방법:(a) 탁산이 55 내지 75 %(w/v)로 용해된 제1 용액을 준비하는 단계;(b) 알부민이 15 내지 25 %(w/v)로 용해된 제2 용액을 준비하는 단계;(c) 제1 용액과 제2 용액을 혼합하여 현탁액을 제조하는 단계; 및(d) 상기 현탁액 부피 기준, 3 내지 12배량의 수성용매로 희석하는 단계.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3235317A CA3235317A1 (en) | 2021-11-03 | 2022-10-31 | Method for producing albumin-bound taxane nanoparticles with improved stability in maintaining particle size distribution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210150107A KR102526793B1 (ko) | 2021-11-03 | 2021-11-03 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
KR10-2021-0150107 | 2021-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023080575A1 true WO2023080575A1 (ko) | 2023-05-11 |
Family
ID=86143488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/016812 WO2023080575A1 (ko) | 2021-11-03 | 2022-10-31 | 입도분포 유지 안정성이 개선된 알부민 결합 탄산 나노입자 제조방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102526793B1 (ko) |
CA (1) | CA3235317A1 (ko) |
WO (1) | WO2023080575A1 (ko) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030078722A (ko) * | 2002-03-29 | 2003-10-08 | 에이씨에스 도브파 에스. 피. 에이. | 파클리탁셀 및 알부민의 나노입자의 제조방법 |
KR20120053052A (ko) * | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
CN106137969A (zh) * | 2015-04-03 | 2016-11-23 | 四川科伦药物研究院有限公司 | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 |
JP2017522297A (ja) * | 2014-07-03 | 2017-08-10 | 石葯集団中奇制葯技▲術▼(石家庄)有限公司Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 精製された治療用ナノ粒子およびその調製方法 |
US9813272B2 (en) | 2007-02-16 | 2017-11-07 | Samsung Electronics Co., Ltd. | OFDM transmitting and receiving systems and methods thereof |
KR20200014279A (ko) * | 2017-06-09 | 2020-02-10 | 크리티테크, 인크. | 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료 |
KR20210150107A (ko) | 2020-06-03 | 2021-12-10 | 주식회사 아이티팩토리 | 클라우드 기반 스마트 haccp 플랫폼 시스템 |
-
2021
- 2021-11-03 KR KR1020210150107A patent/KR102526793B1/ko active IP Right Grant
-
2022
- 2022-10-31 WO PCT/KR2022/016812 patent/WO2023080575A1/ko active Application Filing
- 2022-10-31 CA CA3235317A patent/CA3235317A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030078722A (ko) * | 2002-03-29 | 2003-10-08 | 에이씨에스 도브파 에스. 피. 에이. | 파클리탁셀 및 알부민의 나노입자의 제조방법 |
US9813272B2 (en) | 2007-02-16 | 2017-11-07 | Samsung Electronics Co., Ltd. | OFDM transmitting and receiving systems and methods thereof |
KR20120053052A (ko) * | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
JP2017522297A (ja) * | 2014-07-03 | 2017-08-10 | 石葯集団中奇制葯技▲術▼(石家庄)有限公司Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 精製された治療用ナノ粒子およびその調製方法 |
CN106137969A (zh) * | 2015-04-03 | 2016-11-23 | 四川科伦药物研究院有限公司 | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 |
KR20200014279A (ko) * | 2017-06-09 | 2020-02-10 | 크리티테크, 인크. | 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료 |
KR20210150107A (ko) | 2020-06-03 | 2021-12-10 | 주식회사 아이티팩토리 | 클라우드 기반 스마트 haccp 플랫폼 시스템 |
Non-Patent Citations (1)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY |
Also Published As
Publication number | Publication date |
---|---|
KR102526793B1 (ko) | 2023-04-28 |
CA3235317A1 (en) | 2023-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014133351A1 (en) | Composition for gene delivery comprising chitosan and liquid crystal formation material | |
WO2020197185A1 (en) | Compositions of dispersed phase for preparation of apixaban-loaded microspheres and biocompatible polymer-based apixaban-loaded microspheres prepared therefrom | |
WO2011081406A2 (ko) | 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법 | |
WO2021091246A1 (ko) | 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법 | |
WO2009107983A2 (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
EP3946272A1 (en) | Method for preparing biocompatible polymer-based apixaban-loaded microspheres | |
WO2022010317A1 (ko) | 도네페질 함유 서방출성 plga 미립구의 제조방법 | |
AU2018289188B2 (en) | Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same | |
WO2018147660A1 (ko) | 정신질환 또는 중추신경계 질환 치료용 약물전달 제형 | |
WO2010059001A2 (ko) | 내성암 치료용 고분자 미셀 조성물 및 그 제조방법 | |
WO2021080345A1 (ko) | 약물전달시스템으로서의 안구 주입형 마이크로젤 및 이를 포함하는 하이드로젤 | |
WO2012173458A9 (ko) | 식물 세포 내에 안정화된 활성 물질 및 그 제조방법 | |
WO2023080575A1 (ko) | 입도분포 유지 안정성이 개선된 알부민 결합 탄산 나노입자 제조방법 | |
WO2022005216A1 (ko) | 인지질을 함유하는 약물-점토광물 복합체 및 이를 포함하는 경구투여용 조성물 | |
WO2014208901A1 (ko) | 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법 | |
WO2020242234A1 (ko) | 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법 | |
WO2023038202A1 (ko) | 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법 | |
WO2023101348A1 (ko) | 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법 | |
WO2017052255A1 (ko) | 탁산계 약물 전달용 리포좀 및 이의 제조방법 | |
WO2013115559A1 (ko) | 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법 | |
WO2017142164A1 (ko) | 항암제 약물전달체 및 이의 제조방법 | |
WO2024101859A1 (ko) | 덱사메타손 아세테이트를 포함하는 서방형 주사제제 및 그 제조방법 | |
WO2022164061A1 (ko) | 단백질 제제의 안정성 향상을 위한 단백질 마이크로비드의 제조 방법 | |
WO2019203400A1 (ko) | 항암제 봉입 마이셀 제제 조성물 | |
WO2020105883A1 (ko) | 로티고틴 함유 고분자 미립자의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22890306 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 312197 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235317 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024006978 Country of ref document: BR |